Bristol-Myers Squibb Co (NYSE:BMY) – Jefferies Group raised their FY2017 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a research note issued on Tuesday. Jefferies Group analyst J. Holford now anticipates that the biopharmaceutical company will post earnings of $2.99 per share for the year, up from their previous estimate of $2.98. Jefferies Group has a “Hold” rating and a $72.00 price objective on the stock. Jefferies Group also issued estimates for Bristol-Myers Squibb’s FY2021 earnings at $4.99 EPS.
Several other research firms have also recently weighed in on BMY. Credit Suisse Group reiterated a “hold” rating and set a $61.00 price objective (up previously from $58.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Piper Jaffray Companies reiterated a “hold” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Leerink Swann increased their price objective on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Zacks Investment Research upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Friday. Finally, Vetr cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price objective on the stock. in a research report on Thursday, September 28th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the stock. Bristol-Myers Squibb has a consensus rating of “Hold” and an average target price of $65.11.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter last year, the company posted $0.77 EPS. The firm’s revenue was up 6.7% on a year-over-year basis.
The business also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be given a $0.40 dividend. The ex-dividend date is Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.57%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.99%.
In related news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the transaction, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Theodore R. Samuels II purchased 4,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the transaction, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Massey Quick Simon & CO. LLC boosted its stake in Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 1,492 shares in the last quarter. Horan Capital Advisors LLC. acquired a new stake in Bristol-Myers Squibb in the third quarter valued at about $122,000. Tradewinds Capital Management LLC boosted its stake in Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares in the last quarter. Atlantic Trust LLC acquired a new stake in Bristol-Myers Squibb in the second quarter valued at about $111,000. Finally, AllSquare Wealth Management LLC acquired a new stake in Bristol-Myers Squibb in the third quarter valued at about $134,000. Institutional investors own 69.74% of the company’s stock.
WARNING: “FY2017 EPS Estimates for Bristol-Myers Squibb Co Raised by Jefferies Group (BMY)” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/20/fy2017-eps-estimates-for-bristol-myers-squibb-co-raised-by-jefferies-group-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.